Nivolumab BMS (nivolumab)
- Region
- 🇪🇺 EU
- Active substance
- nivolumab
- Company
- Bristol-Myers Squibb Pharma EEIG
- Status
- Withdrawn
- Therapeutic area
- Carcinoma, Non-Small-Cell Lung
- CHMP opinion
- Thu 21 May 2015
- EU approval
- Mon 20 Jul 2015
- Application
- EMEA/H/C/003840
- ATC
- L01XC17
- Official record
- www.ema.europa.eu
Indication
Nivolumab BMS is indicated for the treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Opdivo Authorised · Bristol-Myers Squibb Pharma EEIG
- 🇪🇺 Opdualag Authorised · Bristol-Myers Squibb Pharma EEIG
Follow Nivolumab BMS
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.